

S1 Fig. The effects of epidermal growth factor receptor (EGFR) and MET tyrosine kinase inhibitors (TKIs) treatment on the viability of human umbilical vein endothelial cell line (HUVEC). Cell viability curve of HUVEC cells treated with increasing doses of lazertinib and vabametkib (fixed dose) for 72 hours (upper) and relative IC50 values from the upper curves (bottom). At least two biological replicates and two technical replicates were performed.